Gofen & Glossberg’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $15M | Sell |
174,810
-5,102
| -3% | -$404K | 0.39% | 63 |
|
|
2022
Q3 | $11.1M | Sell |
179,912
-943
| -0.5% | -$59.5K | 0.31% | 79 |
|
|
2022
Q2 | $11.2M | Sell |
180,855
-22,983
| -11% | -$1.42M | 0.3% | 80 |
|
|
2022
Q1 | $12.1M | Sell |
203,838
-28,118
| -12% | -$1.8M | 0.28% | 85 |
|
|
2021
Q4 | $16.8M | Sell |
231,956
-5,304
| -2% | -$365K | 0.36% | 73 |
|
|
2021
Q3 | $16.6M | Sell |
237,260
-8,383
| -3% | -$589K | 0.39% | 65 |
|
|
2021
Q2 | $16.9M | Sell |
245,643
-20,684
| -8% | -$1.38M | 0.4% | 64 |
|
|
2021
Q1 | $17.2M | Buy |
266,327
+618
| +0.2% | +$39.8K | 0.44% | 57 |
|
|
2020
Q4 | $15.5M | Sell |
265,709
-2,972
| -1% | -$179K | 0.42% | 58 |
|
|
2020
Q3 | $17M | Sell |
268,681
-1,195
| -0.4% | -$82.9K | 0.52% | 51 |
|
|
2020
Q2 | $20.8M | Sell |
269,876
-2,284
| -0.8% | -$175K | 0.7% | 42 |
|
|
2020
Q1 | $20.3M | Sell |
272,160
-1,287
| -0.5% | -$88.9K | 0.8% | 39 |
|
|
2019
Q4 | $17.8M | Sell |
273,447
-6,760
| -2% | -$440K | 0.57% | 51 |
|
|
2019
Q3 | $17.8M | Sell |
280,207
-1,514
| -0.5% | -$99K | 0.6% | 50 |
|
|
2019
Q2 | $19M | Buy |
281,721
+45,266
| +19% | +$2.98M | 0.65% | 50 |
|
|
2019
Q1 | $15.4M | Buy |
236,455
+39,139
| +20% | +$2.6M | 0.54% | 54 |
|
|
2018
Q4 | $12.3M | Sell |
197,316
-9,754
| -5% | -$682K | 0.49% | 60 |
|
|
2018
Q3 | $16M | Sell |
207,070
-3,388
| -2% | -$256K | 0.55% | 58 |
|
|
2018
Q2 | $14.9M | Sell |
210,458
-3,897
| -2% | -$275K | 0.55% | 58 |
|
|
2018
Q1 | $16.2M | Sell |
214,355
-6,444
| -3% | -$512K | 0.61% | 53 |
|
|
2017
Q4 | $15.8M | Sell |
220,799
-22,249
| -9% | -$1.69M | 0.57% | 59 |
|
|
2017
Q3 | $19.7M | Sell |
243,048
-15,748
| -6% | -$1.2M | 0.73% | 40 |
|
|
2017
Q2 | $18.3M | Sell |
258,796
-13,477
| -5% | -$897K | 0.7% | 46 |
|
|
2017
Q1 | $18.5M | Sell |
272,273
-12,368
| -4% | -$870K | 0.72% | 41 |
|
|
2016
Q4 | $20.4M | Sell |
284,641
-15,077
| -5% | -$1.12M | 0.83% | 34 |
|
|
2016
Q3 | $23.7M | Sell |
299,718
-5,780
| -2% | -$470K | 0.98% | 27 |
|
|
2016
Q2 | $25.5M | Sell |
305,498
-6,100
| -2% | -$541K | 1.07% | 27 |
|
|
2016
Q1 | $28.6M | Buy |
311,598
+4,912
| +2% | +$443K | 1.22% | 24 |
|
|
2015
Q4 | $31M | Buy |
306,686
+9,945
| +3% | +$1.03M | 1.35% | 22 |
|
|
2015
Q3 | $29.1M | Buy |
296,741
+567
| +0.2% | +$63K | 1.33% | 22 |
|
|
2015
Q2 | $34.7M | Buy |
296,174
+4,353
| +1% | +$476K | 1.46% | 17 |
|
|
2015
Q1 | $28.6M | Buy |
291,821
+46,495
| +19% | +$4.72M | 1.23% | 24 |
|
|
2014
Q4 | $23.1M | Sell |
245,326
-943
| -0.4% | -$97.5K | 0.99% | 28 |
|
|
2014
Q3 | $26.2M | Sell |
246,269
-4,802
| -2% | -$470K | 1.16% | 22 |
|
|
2014
Q2 | $20.8M | Buy |
251,071
+1,399
| +0.6% | +$109K | 0.92% | 28 |
|
|
2014
Q1 | $20.7M | Sell |
249,672
-7,965
| -3% | -$625K | 0.96% | 25 |
|
|
2013
Q4 | $19.3M | Sell |
257,637
-10,544
| -4% | -$734K | 0.91% | 30 |
|
|
2013
Q3 | $16.9M | Sell |
268,181
-15,914
| -6% | -$951K | 0.87% | 32 |
|
|
2013
Q2 | $14.6M | Buy |
+284,095
| New | +$14.8M | 0.79% | 37 |
|
Other funds holding GILD
Gofen & Glossberg's GILD Position: Q4 2022 in Review
Gofen & Glossberg reduced its Gilead Sciences (GILD) stake by 2.8% in Q4 2022, selling an estimated $404K and leaving 174,810 shares worth $15M. The position accounts for 0.39% of the portfolio, ranked #63.
Gofen & Glossberg first reported a position in GILD in Q2 2013 and has held it in 39 quarters since. The position peaked at $34.7M in Q2 2015. 1,768 funds tracked by Wall St. Rank hold GILD as of Q4 2022.
- Gofen & Glossberg held 174,810 shares of Gilead Sciences worth $15M as of Q4 2022.
- Gofen & Glossberg sold 5,102 Gilead Sciences shares in Q4 2022, an estimated $404K.
- Gilead Sciences made up 0.39% of Gofen & Glossberg's portfolio in Q4 2022, its #63 holding.
- Gofen & Glossberg first reported a position in Gilead Sciences in Q2 2013 and has held it in 39 quarters since.
- Gofen & Glossberg's Gilead Sciences position peaked at $34.7M in Q2 2015.
- 1,768 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2022.
Based on Gofen & Glossberg's 13F filing for Q4 2022, filed 13 Jan 2023.